Crofelemer

Jump to

May not see 35% growth in H1 sustaining in H2: Glenmark

Glenn Saldanha, MD & CEO, Glenmark said the pharma major is growth at the rate of 30% in the Indian market and is confident of maintaining margins ahead.
A bitter pill: Glenmark-Napo Pharma deal off

It is a setback for Indian pharma major Glenmark. The US based Napo Pharma has terminated their mutual contract for Crofelemer, a diarrhoeal drug with huge opportunity in emerging markets.
Glenmark gets USD 15m plant upgradation advance from Salix

Glenmark Pharmaceuticals today said it has received USD 15 million (over Rs 65 crore) from Salix Pharmaceuticals Inc, USA, as an advance payment to upgrade its plant for production of Crofelemer, used for treating diarrhoea.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Crofelemer

May not see 35% growth in H1 sustaining in H2: Glenmark

A bitter pill: Glenmark-Napo Pharma deal off

Glenmark gets USD 15m plant upgradation advance from Salix